Daunorubicin and alanine aminotransferase increased Patient Reports February 11, 2012

Daunorubicin Side Effects Report #4670398-8
Daunorubicin side effect was reported by a Consumer or non-health professional from on May 11, 2005. Female patient, 17 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Daunorubicin. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood albumin decreased, blood alkaline phosphatase increased, blood bilirubin increased, blood bilirubin unconjugated increased, blood cholinesterase decreased, blood fibrinogen decreased, cholestasis. Daunorubicin dosage: 45 MG/M2. During the same period patient was treated with VINCRISTINE, CYLOPHOSPHAMIDE, ASPARAGINASE, PREDNISOLONE. Patient recovered.

Daunorubicin Side Effects Report #4680263-8
Daunorubicin side effect was reported by a Consumer or non-health professional from on May 11, 2005. Female patient, 17 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Daunorubicin. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, bilirubin conjugated increased, blood albumin decreased, blood alkaline phosphatase increased, blood bilirubin increased, blood cholinesterase decreased, blood fibrinogen decreased, gamma-glutamyltransferase increased. Daunorubicin dosage: 45 MG/M2. During the same period patient was treated with VINCRISTINE, CYCLOPHOSPHAMIDE, ASPARAGINASE, PREDNISOLONE. Patient recovered.

Daunorubicin Side Effects Report #5273551-8
Daunorubicin side effect was reported by a Consumer or non-health professional from UNITED STATES on Mar 21, 2007. Female patient, weighting 66.14 lb, was treated with Daunorubicin. After drug was administered, patient experienced the following side effects: abdominal pain , agitation, alanine aminotransferase increased, anaemia, aspartate aminotransferase increased, blood fibrinogen decreased, blood phosphorus increased, blood potassium increased, blood urea increased. Daunorubicin dosage: 53 MG. During the same period patient was treated with DEXAMETHASONE, METHOTREXATE, VINCRISTINE SULPHATE, CYTARABINE. Patient recovered.

Daunorubicin Side Effects Report #5390181-8
Daunorubicin side effect was reported by a Consumer or non-health professional from UNITED STATES on July 16, 2007. Female patient, weighting 183.0 lb, was treated with Daunorubicin. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, alanine aminotransferase increased, aspartate aminotransferase increased, aspergillosis, blood bilirubin increased, febrile neutropenia, fungaemia, hepatic function abnormal, hepatic steatosis. Daunorubicin dosage: 4 MG. During the same period patient was treated with DEXAMETHASONE. Patient was hospitalized. Patient recovered.


Daunorubicin Side Effects Report #5400118-0
Daunorubicin side effect was reported by a Consumer or non-health professional from UNITED STATES on July 27, 2007. Female patient, weighting 183.0 lb, was treated with Daunorubicin. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, acute lymphocytic leukaemia, alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, computerised tomogram abnormal, fungaemia, fungal infection , hepatic function abnormal. Daunorubicin dosage: 4 MG. During the same period patient was treated with DEXAMETHASONE, METHOTREXATE, VINCRISTINE SULPHATE. Patient was hospitalized. Patient recovered.

Daunorubicin Side Effects Report #5898031-8
Daunorubicin side effect was reported by a Consumer or non-health professional from UNITED STATES on Sept 24, 2008. Female patient, weighting 9.99 lb, was treated with Daunorubicin. After drug was administered, patient experienced the following side effects: abdominal distension, alanine aminotransferase increased, ascites, blood bilirubin increased, hepatomegaly, hepatotoxicity, venoocclusive liver disease. Daunorubicin dosage: 14MG. During the same period patient was treated with METHOTREXATE, VINCRISTINE SULPHATE, CYCLOPHOSPHAMIDE, CYTARABINE, ACTIGALL, CIPROFLOXACIN, DAPSONE. Patient recovered.